

UNIVERSITY OF TEXAS REGENERA ADVANCED CELL THERAPEUTICS & RESEARCH CENTER STEM CELL REGENERATIVE PROGRAMS, PRECISION IMMUNOTHERAPIES, MOLECULAR & **CELLULAR DISEASE MANAGEMENT**

SECTION 1: PATIENT DEMOGRAPHICS

Full Legal Name: [Prefix	x] \square Mr. \square Mrs. \square M	ls. 🗆 Dr. 🗆 Other:		
First: Middle				
Date of Birth: DD / MM				
Gender Identity: □ Ma	le □ Female □ Non-l		to say 🗆 Other:	
National ID/Passport: _ Issuing Country:		nber:	EXAS	
Ethnicity	(For genetic diso	rder profiling)	rsor	
Immunization Records				
• Last Tetanus Shot: /_	□ Up to date 〔	☐ Not up to date	~-~+~-	4.6
• COVID-19 Vaccinatio	n: 🗆 Yes (Doses:	□No		
Other Vaccines:				
FAMILY MEDICAL HISTO	ORV			
		TT:		
• ☐ Hypertension ☐	Diabetes ☐ Heart [Disease □ Cancer	☐ Stroke ☐ Genetic Dis	orders
• Specify relation (e.g.,				
, , , , , , , , , , , , , , , , , , , ,	, ,			
<u>.</u>	SECTION 2: CONTACT	& EMERGENCY INFO	<u>DRMATION</u>	
Primary Address Stre	et·			
			Country:	
			 Email:	
			Phone:	
Emergency Contact (2)	lName:	Relationship:	Phone:	



SECTION 3: PRE-TREATMENT WORKUP

Laboratory Tests Conducted:		
Complete Blood Count:		
• Tumor Markers (if cancer):		
Genetic Testing (if applicable):		
Imaging:		
☐ MRI ☐ CT ☐ PET Scan ☐ Echocar	diogram □ Bone Scan	
Findings:		
Biopsy/Pathology Report (if cancer):		- 1-1
• Tumor Grade: Genetic N	Mutations (e.g., BRCA, K	RAS):
Vital Signs:	SITY OF	TEXAS
		Oxygen Saturation:
Temperature: Body Weigh	t:	
SECTION 4. PRIA	AADV DIACNOSIS 8 SDE	CIALIZATION AREA
SECTION 4: PRIN	MARY DIAGNOSIS & SPE	CIALIZATION AREA
(Check all applicable specialties & sp	pecify conditions)	
	e Category / Specific Co	ndition(s)
and a second		
	☐ 1. Cancer	
Breast / Prostate / Lung / Colorectal		Hodgkin Lymphoma / Kidney /
Pancreatic / Leukemias / Thyroid / L		• , ,
Making Can	☐ 2. Neuro Disorders	ory
Stroke (\square Ischemic \square Hemorrhagic	☐ TIA) / Alzheimer's / P	'arkinson's / ALS / Huntington's /
Frontotemporal Dementia / MS / Gu	uillain-Barré / Epilepsy /	ASD / ADHD
	☐ 3. Cardiovascular	
HFrEF / HFpEF / PAD / Cardiomyopa		
Atherosclerosis / Arrhythmia (□ Atr	ial Fibrillation □ Ventric	cular Tachycardia)
Lunus (SLE) / DA / Siägron/s / Timos	□ 4. Autoimmune	s / Musethania Cravis / Crab-/-/
Lupus (SLE) / RA / Sjögren's / Type 1 Ulcerative Colitis / Psoriasis	T DIANETES / HAZIIIIIIOTO	5 / IVIYASUTETIIA GTAVIS / CTOTTI S /



☐ 5. Genetic/Cell Disorders Gaucher / Niemann-Pick / Fabry / Glycogen Storage / Mitochondrial (□ MELAS □ Leigh □ Kearns-Sayre) / Sickle Cell / Thalassemia / Aplastic Anemia / Duchenne MD / Cystic Fibrosis / Marfan / Ehlers-Danlos ☐ 6. Immunodeficiencies SCID / CVID / DiGeorge / HIV/AIDS / Chemotherapy-Induced ☐ 7. Organ Damage/Failure Cirrhosis / Hepatitis (□ B □ C) / Alcoholic Liver / CKD / Glomerulonephritis / Polycystic Kidney / Pulmonary Fibrosis (☐ Idiopathic ☐ Silicosis) □ 8. Musculoskeletal Osteoarthritis / Osteoporosis / Non-Healing Fracture / Osteogenesis Imperfecta / Rhabdomyolysis ☐ 9. Skin/Wound Disorders Diabetic Ulcer / Venous Stasis Ulcer / Severe Burns / Keloids / Hypertrophic Scars / Epidermolysis Bullosa / Pemphigus □ 10. Eye Disorders Macular Degeneration (Dry Wet) / Keratoconus / Corneal Dystrophy / Glaucoma / Retinitis Pigmentosa ☐ 11. Aging-Related Frailty Syndrome / Osteoporosis / Sarcopenia / Cognitive Decline Date of Initial Diagnosis: _____ Referred By: □ Physician (Name:) □ Self □ Other:



SECTION 5: MEDICAL HISTORY & CURRENT TREATMENTS

List of Current Medications (Name, Dose, Frequency):				
1)				
2)				
3)				
4)				
5)				
Allergies Drug/Food/Other: Reaction:				
Past Surgeries Procedure: Date: Hospital:				
Previous Therapies Chemo/Radiation/Stem Cell/Immunotherapy/Other:				
Genetic Testing Done? ☐ Yes (Upload report) ☐ No ☐ Pending				
SECTION 6: STEM CELL THERAPY ELIGIBILITY CRITERIA				
Condition-Specific Protocol (Match to primary diagnosis):				
☐ CAR-T Cell Therapy (Leukemia, Lymphoma)				
☐ Cardiac Progenitor Cells (Heart Failure)				
☐ Mesenchymal Stem Cells (Osteoarthritis, Bone Fractures)				
☐ Hematopoietic Stem Cell Transplant (MS, Sickle Cell Anemia)				
☐ Retinal Stem Cells (Macular Degeneration)				
☐ Neural Stem Cells (Stroke, Alzheimer's/Parkinson's)				
☐ Gene-Edited Stem Cells (Cystic Fibrosis, Duchenne MD)				
☐ Autologous Skin Grafts (Burns/Chronic Wounds)				
□ Other:				
ELICIDII ITV SCREENING				
ELIGIBILITY SCREENING				
☐ Confirmed diagnosis via biopsy/imaging/lab results (Attach reports).				
☐ Failed standard therapies (e.g., chemotherapy, immunosuppressants).				
\square Adequate organ function (e.g., LVEF >40% for cardiac therapy).				
\square No active infections or untreated malignancies (exceptions: cancer patients).				
☐ Patient consents to experimental/off-label use.				



SECTION 7: ADVANCED THERAPY INTEREST & CONSENT

(Select therapies of interest) Research-Based Programs consent for Data Use Search based programes Consent data use stem cell regenerative programe \square consent to my anonymized data being used for research ☐ consent to biopsy/genetic material storage (5 years) BiTEs / Trispecific Antibodies TCR-T Cell Therapy Cancer-Killing Bacteria Treatment Risks Acknowledgement I understand these therapies are innovative and may involve Sonodynamic Therapy (SDT) unknown risks Ferroptosis Inducers Photothermal/Photodynamic (PTT/PDT) mRNA Cancer Vaccines Signature: Date: Exosome-Based Therapies Epigenetic Editing Al-Designed Drug Combinations **SECTION 8: LIFESTYLE & SUPPORT SYSTEM** Tobacco/Alcohol Use | ☐ Never ☐ Former ☐ Current (Frequency: ___ Diet/Exercise | ☐ Sedentary ☐ Light Activity ☐ Moderate ☐ Intensive Living Situation | □ Alone □ With Family □ Assisted Facility Primary Caregiver | Name: _____ Contact: _____ Relationship: _

SECTION 9: INSURANCE, REGISTRATION FEE & FINANCIAL RESPONSIBILITY

Primary Insurance Provider:	Policy #: _	
Group #:	Expiry: DD / MM / YYYY	
Secondary Insurance Provider:	Policy#:	
Financial Guarantor Name:	Relationship:	Contact:
1. Registration Fee		
Amount: \$412 (Non-refundable)		
Purpose: Covers administrative procassessment.	essing, initial specialist consul	tation, and medical candidacy
Final amount confirmed during cons	sultation scheduling. Price lock	ed for 72h after invoice.
2. Payment Method	SITY OF TE	XAS
(✓ Select one option)	1	
[] Credit/Debit Card	1000	2002
Cardholder Name:		(S(t))
Card Number:	Expiry:/ CVV:	LOOII
[] Bank Transfer Account details provided upon sub	mission	enter
[] Financing Plan		
Selected plan: (Coord	inator will contact you)	
3. Fee Coverage Details This fee includes:	cer History	
- [x] Medical history review & digital	records processing	
- [x] 45-min initial specialist consulta		
- [x] Treatment candidacy assessme		
- [] Diagnostics/imaging (billed sepa	rately)	
4. Financial Policies		
☐ I understand:		
- Registration fee non-refundable if	canceled <72h prior	
- Fee applicable toward treatment c	osts within 90 days	
- No insurance coverage per FDA/EN	ЛА experimental status	



5. Discounts & Assistance	
- [] Research participation discount (IRB s	study ID:)
- [] Sliding-scale fee consideration (Attack	,,
- [] Military/VA benefits inquiry	
[],	
6. Refund Protocol	
- Refunds processed in USD within 5 bu	siness days
- Historical rate documentation provide	ed
·	
SECTION 1	.0: PATIENT DECLARATION
<u> </u>	O. I ATTENT DEGLA WATTON
I certify that all information provided is a	ccurate. I authorize MD Anderson to share medical dat
·	derstand that falsification may impact treatment
outcomes.	
	naercan
Patient Signature:	Date:
Witness (Staff):	ID Badge #:
	ri enier
Administrative Use Only	
Admitting Physician: Dr.	Dept:
Patient ID: REG202_	
Priority Status ☐ Urgent (24h) ☐ High (7	72h) □ Standard (1-2 weeks)
Initial Assessment Notes	er History
-	